UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION
12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE
REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
COMMISSION FILE NUMBER001-08366
POLYDEX PHARMACEUTICALS LIMITED |
| (Exact name of small business issuer as specified in its charter) |
| 421 Comstock Road, Toronto, Ontario |
| Canada, M1L 2H5 |
| (Address of principal executive offices) |
| (416) 755-2231 |
| Issuer's telephone number |
Common Shares, Par Value $0.0167 Per Share |
| (Title of each class of securities covered by this Form) |
None |
| (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains) |
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
| Rule 12g-4(a)(1) | [ ] | ||
| Rule 12g-4(a)(2) | [ X ] | ||
| Rule 12h-3(b)(1)(i) | [ ] | ||
| Rule 12h-3(b)(1)(ii) | [ X ] | ||
| Rule 15d-6 | [ ] |
Approximate number of holders of record as of the certification or notice date: 335
Pursuant to the requirements of the Securities Exchange Act of 1934 Polydex Pharmaceuticals Limitied. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
| POLYDEX PHARMACEUTICALS LIMITED | ||
| Date: May 7, 2010 | By: | /s/ George G. Usher |
| President & Chief Executive Officer | ||
